MDM2 x VEGFR

At the onset of training, each exercise session transiently shifts the distribution of histone post‐transcriptional modifications (HPTMs) to activate genes that drive muscle adaptations. The resulting cyclic changes in gene expression promote the acquisition of high oxidative capacities and gains in capillaries. If training stops or remains at the same intensity, adaptation ceases. Whether silencing HPTMs helps to halt adaptation remains understudied. The E3 ubiquitin ligase murine double minute (MDM2) and enhancer of zester homolog 2 (EZH2) interact and tri‐methylate histone H3 on lysine 27 (H3K27me3), silencing genes. C57Bl6 mice ran for 9 weeks (5 days a week) maintaining a constant running speed for the last 5 weeks of training. Muscles were collected 72 h after the last run. Training increased MDM2 and EZH2 proteins and led to an H3K27me3 enrichment in Kdr and Notch1 regulatory sequences. Kdr mRNA levels decreased, following the canonical model that H3K27me3 silences genes. Notch1 mRNA increased. Trained muscles had greater levels of H3K27me3 detected at 25 kDa and no change at the expected molecular weight of 17 kDa. The 25 kDa band was identified as a ubiquitylated form of H3 (H3Ub). C2C12 myotubes exposed to four consecutive days of 90 min electrostimulation had higher levels of H3Ub. EZH2 inhibition counteracted the electrostimulation‐driven accumulation of H3Ub and increased Notch1 mRNA. Serdemetan, an MDM2 ring domain inhibitor, reduced Notch1 mRNA and H3Ub level in myotubes. MDM2‐dependent ubiquitylation of H3 might upregulate Notch1 when endurance training ceases. The role H3Ub plays in establishing a new muscle homeostasis remains unclear. image

Whether epigenetic silencing histone marks play a role once skeletal muscle adaptations have occurred following endurance training remains unclear.The E3 ubiquitin ligase MDM2 and the epigenetic writer EZH2 interact to establish H3K27me3 marks that silence genes, and endurance training increased the expression of both proteins.After weeks of training new capillaries were established, and lower levels of Kdr mRNA and increased H3K27me3 marking on Kdr regulatory sequences question whether silencing of this positive regulator of angiogenesis is required to halt microvascular remodelling.Training increases skeletal muscle abundance of a ubiquitylated form of H3 (H3Ub); in myotubes EZH2 inhibition limits H3Ub accumulation after contractile activity repeated over 4 days and MDM2 inhibition reduces H3Ub levels and upregulates Notch1 expression.MDM2‐dependent ubiquitylation of H3 might explain why H3K27me3 enrichment fails to silence Notch1 after training; whether H3Ub is crucial to halt adaptation and establish a new muscle homeostasis requires further investigation.

Cancer is a global disease that causes millions of deaths annually, with gastrointestinal cancers becoming more prevalent than lung and breast cancers. Lifestyle factors like smoking and unhealthy eating habits increase the risk of cancer. Precision medicine approaches are needed to improve patient outcomes and cancer survival rates. Genistein, a natural isoflavonoid, acts as an anticancer medication by inducing apoptosis, preventing metastasis, and triggering cell death. It relies on various signaling pathways, including JAK1/2‐STAT3, AKT/MDM2, EGFR, MEK/ERK, Shh‐Gli1, MMP‐2, FLT4, STAT3, PLK‐1, and others. Elevated serum concentrations of isoflavones like genistein and daidzein have been linked to a decreased incidence of stomach cancer. Consumption of genistein through diet has been linked to potential health benefits, such as heart disease prevention, gastrointestinal, prostate, and breast cancer prevention through chemotherapy, and alleviation of postmenopausal symptoms. Genistein is a potent anticancer medication that works against various cancer types. This review examines the pharmacokinetics, chemistry, and possible applications of genistein in the treatment of pancreatic, esophageal, gastric, liver, and colorectal malignancies. The utilization of nanotechnology in conjunction with genistein is also discussed.

A review.Originating from chromosomal DNA, ecDNA primarilyforms through mechanisms associated with chromosomal instability, such as DNA damage repair, chromothripsis,episome formation, and the breakageefusionebridge cycle.Ranging in size from 100 kb to several Mb, ecDNA is distinct from smaller extrachromosomal circular DNA (eccDNA) found in both tumor and normal eukaryotic cells.EcDNA confers cancer cells with significant advantages in proliferation and energy metabolism, while also contributing to tumor heterogeneity and malignancy.The eDyNAmiC project further reported that 17.1% of tumor samples in the 100,000 Genomes Project (100kGP) harbor ecDNA, with the highest prevalence in liposarcoma (54.9%), GBM (49.1%), and HER2-pos. breast cancer (46.4%) patients2.Imaging techniques, such as electron microscopy, fluorescence in situ hybridization, and live-cell imaging with ecTag, are effective but are limited by the need for metaphase preparation, prior DNA sequencing, and low throughput.However, the development of clin. viable and cost-effective ecDNA detection tools remains a challenge.The 100kGP project revealed that while ecDNAs predominantly amplify oncogenes, they also carry immunomodulatory genes.In the TCGA GBMLGG cohort, ecDNA frequently carries genes located on chromosomes 1, 4, 7, and 12, including well-known oncogenes such as CDK4, MDM2, SOX2, and EGFR, all recognized as tumor drivers by the GISTIC algorithm and/or listed in OncoKB.EcDNA also carries immunomodulatory genes like KDR and LAG3, which contribute to immune evasion.The circular structure of ecDNA facilitates the spatial proximity of DNA elements and oncogenes, enabling a phenomenon known as enhancer hijacking.Microsatellite instability (MSI) was significantly lower, consistent with the well-established pan-cancer pattern of mutual exclusivity between ecDNA amplification and MSI.Interestingly, we observed that ploidy was not elevated in ecDNApos. samples, and that these samples exhibited increased purity, a result that deviates from typical pan-cancer trends.No significant differences were observed between unamplified and linear-amplified groups, suggesting that ecDNA-driven amplification has a more profound impact on glioma progression than linear amplification alone.